AQST Shareholder Alert: False Statements Impact Stock Price
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy AQST?
Source: Globenewswire
- False Statements Allegation: The complaint alleges that AQST misled investors by providing positive statements while concealing significant adverse facts regarding its New Drug Application for Anaphylm, which has severely impacted shareholder confidence.
- FDA Deficiency Letter: On January 9, 2026, AQST disclosed that it received a letter from the FDA identifying deficiencies that hindered labeling discussions, indicating that the approval of Anaphylm would be delayed, thus affecting the company's future revenue expectations.
- Dramatic Stock Decline: Following the FDA announcement, AQST's stock plummeted from $6.21 per share on January 8, 2026, to $3.91 per share on January 9, representing a decline of over 37% in a single day, reflecting extreme market pessimism about the company's outlook.
- Shareholder Action Call: The Gross Law Firm urges shareholders who purchased AQST stock between June 16, 2025, and January 8, 2026, to register for participation in the class action lawsuit to protect their rights and seek recovery, with a deadline of May 4, 2026.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AQST?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AQST
Wall Street analysts forecast AQST stock price to rise
7 Analyst Rating
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 4.150
Low
6.00
Averages
9.00
High
12.00
Current: 4.150
Low
6.00
Averages
9.00
High
12.00
About AQST
Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is engaged in developing orally administered and topical gel products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. It has four commercialized products marketed by the Company’s licensees in the United States and around the world and is the manufacturer of these licensed products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary technologies, including PharmFilm, and has proven drug development and commercialization capabilities. The Company is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an early-stage epinephrine prodrug topical gel product candidate for various possible dermatology conditions. Its portfolio includes Anaphylm, AQST-108, Libervant, Suboxone, and Emylif.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Class Action Lawsuit Filed Against Aquestive Therapeutics
- Class Action Initiation: Pomerantz LLP has announced a class action lawsuit against Aquestive Therapeutics, alleging securities fraud by the company and certain executives, with investors needing to apply as Lead Plaintiff by May 4, 2026.
- FDA Approval Delay: On January 9, 2026, Aquestive received a letter from the FDA identifying deficiencies in the NDA for Anaphylm (Dibutepinephrine), preventing labeling discussions and leading to indefinite delays in approval, which could impact future product launches.
- Significant Stock Drop: Following the FDA news, Aquestive's stock price fell by $2.30, or 37.04%, closing at $3.91 per share on January 9, 2026, indicating market concerns regarding the company's future prospects.
- Legal Firm Background: Pomerantz LLP is a prominent law firm specializing in securities class actions, founded over 85 years ago, and has a history of recovering multimillion-dollar damages for victims of securities fraud, underscoring its commitment to protecting investor rights.
See More
Shareholder Alert for Aquestive Therapeutics
- Shareholder Action Notice: The Gross Law Firm has issued a notice encouraging shareholders who purchased AQST shares between June 16, 2025, and January 8, 2026, to contact the firm regarding potential lead plaintiff appointment, facilitating participation in possible recovery.
- FDA Regulatory Issues: On January 9, 2026, Aquestive disclosed receipt of a letter from the FDA identifying deficiencies in its New Drug Application, which precluded labeling discussions and significantly delayed the approval timeline for Anaphylm, undermining investor confidence.
- Stock Price Plunge: Following the FDA notification, AQST's stock price plummeted from $6.21 per share on January 8, 2026, to $3.91 per share on January 9, 2026, marking a dramatic decline of over 37% in a single day, reflecting market pessimism regarding the company's future prospects.
- Litigation Participation Deadline: Shareholders must register by May 4, 2026, to participate in the class action lawsuit, with the Gross Law Firm committed to providing portfolio monitoring services to keep investors informed about the case's progress and protect their rights.
See More
Class Action Lawsuit Filed Against Aquestive Therapeutics
- Lawsuit Background: Bragar Eagel & Squire, P.C. has announced a class action lawsuit against Aquestive Therapeutics on behalf of investors who purchased securities between June 16, 2025, and January 8, 2026, aiming to protect investor rights and seek compensation.
- FDA Deficiency Disclosure: The complaint alleges that the company made false statements during the class period, claiming its New Drug Application (NDA) would be approved by January 31, 2026, while the FDA actually identified deficiencies that delayed the approval of Anaphylm.
- Stock Price Plunge: Following the announcement on January 9, 2026, that the FDA had identified deficiencies, Aquestive's stock price plummeted from $6.21 to $3.91, a decline of over 37%, reflecting strong market concerns about the company's future.
- Investor Action: Investors must apply by May 4, 2026, to be appointed as lead plaintiffs in the lawsuit, indicating a growing concern among investors regarding the company's governance and transparency.
See More
Reminder of Class Action for Aquestive Therapeutics Investors
- Class Action Notice: Rosen Law Firm reminds investors who purchased Aquestive Therapeutics (NASDAQ: AQST) securities between June 16, 2025, and January 8, 2026, that they must apply to be lead plaintiff by May 4, 2026, to participate in the class action and potentially receive compensation.
- Fee Arrangement: Investors joining the class action will incur no upfront costs, as the law firm will operate on a contingency fee basis, ensuring that investors can seek legal recourse without financial burden.
- Case Background: The lawsuit alleges that the defendants failed to disclose the true state of Aquestive's New Drug Application (NDA), particularly regarding human factors related to the use and deployment of its sublingual film, resulting in investor losses when the truth emerged.
- Law Firm Advantage: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked No. 1 by ISS Securities Class Action Services in 2017, demonstrating its expertise and successful track record in this field.
See More
Aquestive Faces Class Action Over Delayed Drug Approval
- Class Action Initiated: The Portnoy Law Firm advises investors who purchased Aquestive Therapeutics (NASDAQ: AQST) securities between June 16, 2025, and January 8, 2026, that they can file a lead plaintiff motion by May 4, 2026, indicating significant investor concern over potential losses.
- FDA Deficiency Disclosure: On January 9, 2026, Aquestive disclosed that its New Drug Application (NDA) faced deficiencies identified by the FDA, preventing discussions on labeling and post-marketing commitments, severely undermining investor confidence in the company's future prospects.
- Stock Price Plummet: Following the FDA deficiency disclosure, Aquestive's stock price fell by over 37%, reflecting market disappointment over the company's failure to secure timely approval for Anaphylm, which directly impacts investors' financial positions.
- Legal Consultation Services: The Portnoy Law Firm offers complimentary case evaluations and encourages investors to reach out to discuss their legal rights to recover losses, demonstrating the firm's commitment to protecting investor interests.
See More
Class Action Notice for Aquestive Therapeutics Investors
- Class Action Timeline: Rosen Law Firm reminds investors who purchased Aquestive Therapeutics (NASDAQ:AQST) securities between June 16, 2025, and January 8, 2026, that they must apply to be lead plaintiff by May 4, 2026, to participate in the class action and seek compensation.
- Transparent Fee Structure: Investors joining the class action will incur no upfront costs, as the law firm will operate on a contingency fee basis, ensuring that investors can pursue compensation without financial burden.
- Case Background: The lawsuit alleges that the defendants made false and/or misleading statements regarding their New Drug Application (NDA) and failed to disclose the significance of human factors in the use of their sublingual film, resulting in investor losses when the truth emerged.
- Law Firm's Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, showcasing its expertise and successful track record in this field.
See More
Class Action Lawsuit Filed Against Aquestive Therapeutics
- Class Action Initiation: Pomerantz LLP has announced a class action lawsuit against Aquestive Therapeutics, alleging securities fraud by the company and certain executives, with investors needing to apply as Lead Plaintiff by May 4, 2026.
- FDA Approval Delay: On January 9, 2026, Aquestive received a letter from the FDA identifying deficiencies in the NDA for Anaphylm (Dibutepinephrine), preventing labeling discussions and leading to indefinite delays in approval, which could impact future product launches.
- Significant Stock Drop: Following the FDA news, Aquestive's stock price fell by $2.30, or 37.04%, closing at $3.91 per share on January 9, 2026, indicating market concerns regarding the company's future prospects.
- Legal Firm Background: Pomerantz LLP is a prominent law firm specializing in securities class actions, founded over 85 years ago, and has a history of recovering multimillion-dollar damages for victims of securities fraud, underscoring its commitment to protecting investor rights.
See More
Shareholder Alert for Aquestive Therapeutics
- Shareholder Action Notice: The Gross Law Firm has issued a notice encouraging shareholders who purchased AQST shares between June 16, 2025, and January 8, 2026, to contact the firm regarding potential lead plaintiff appointment, facilitating participation in possible recovery.
- FDA Regulatory Issues: On January 9, 2026, Aquestive disclosed receipt of a letter from the FDA identifying deficiencies in its New Drug Application, which precluded labeling discussions and significantly delayed the approval timeline for Anaphylm, undermining investor confidence.
- Stock Price Plunge: Following the FDA notification, AQST's stock price plummeted from $6.21 per share on January 8, 2026, to $3.91 per share on January 9, 2026, marking a dramatic decline of over 37% in a single day, reflecting market pessimism regarding the company's future prospects.
- Litigation Participation Deadline: Shareholders must register by May 4, 2026, to participate in the class action lawsuit, with the Gross Law Firm committed to providing portfolio monitoring services to keep investors informed about the case's progress and protect their rights.
See More
Class Action Lawsuit Filed Against Aquestive Therapeutics
- Lawsuit Background: Bragar Eagel & Squire, P.C. has announced a class action lawsuit against Aquestive Therapeutics on behalf of investors who purchased securities between June 16, 2025, and January 8, 2026, aiming to protect investor rights and seek compensation.
- FDA Deficiency Disclosure: The complaint alleges that the company made false statements during the class period, claiming its New Drug Application (NDA) would be approved by January 31, 2026, while the FDA actually identified deficiencies that delayed the approval of Anaphylm.
- Stock Price Plunge: Following the announcement on January 9, 2026, that the FDA had identified deficiencies, Aquestive's stock price plummeted from $6.21 to $3.91, a decline of over 37%, reflecting strong market concerns about the company's future.
- Investor Action: Investors must apply by May 4, 2026, to be appointed as lead plaintiffs in the lawsuit, indicating a growing concern among investors regarding the company's governance and transparency.
See More
Reminder of Class Action for Aquestive Therapeutics Investors
- Class Action Notice: Rosen Law Firm reminds investors who purchased Aquestive Therapeutics (NASDAQ: AQST) securities between June 16, 2025, and January 8, 2026, that they must apply to be lead plaintiff by May 4, 2026, to participate in the class action and potentially receive compensation.
- Fee Arrangement: Investors joining the class action will incur no upfront costs, as the law firm will operate on a contingency fee basis, ensuring that investors can seek legal recourse without financial burden.
- Case Background: The lawsuit alleges that the defendants failed to disclose the true state of Aquestive's New Drug Application (NDA), particularly regarding human factors related to the use and deployment of its sublingual film, resulting in investor losses when the truth emerged.
- Law Firm Advantage: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked No. 1 by ISS Securities Class Action Services in 2017, demonstrating its expertise and successful track record in this field.
See More
Aquestive Faces Class Action Over Delayed Drug Approval
- Class Action Initiated: The Portnoy Law Firm advises investors who purchased Aquestive Therapeutics (NASDAQ: AQST) securities between June 16, 2025, and January 8, 2026, that they can file a lead plaintiff motion by May 4, 2026, indicating significant investor concern over potential losses.
- FDA Deficiency Disclosure: On January 9, 2026, Aquestive disclosed that its New Drug Application (NDA) faced deficiencies identified by the FDA, preventing discussions on labeling and post-marketing commitments, severely undermining investor confidence in the company's future prospects.
- Stock Price Plummet: Following the FDA deficiency disclosure, Aquestive's stock price fell by over 37%, reflecting market disappointment over the company's failure to secure timely approval for Anaphylm, which directly impacts investors' financial positions.
- Legal Consultation Services: The Portnoy Law Firm offers complimentary case evaluations and encourages investors to reach out to discuss their legal rights to recover losses, demonstrating the firm's commitment to protecting investor interests.
See More
Class Action Notice for Aquestive Therapeutics Investors
- Class Action Timeline: Rosen Law Firm reminds investors who purchased Aquestive Therapeutics (NASDAQ:AQST) securities between June 16, 2025, and January 8, 2026, that they must apply to be lead plaintiff by May 4, 2026, to participate in the class action and seek compensation.
- Transparent Fee Structure: Investors joining the class action will incur no upfront costs, as the law firm will operate on a contingency fee basis, ensuring that investors can pursue compensation without financial burden.
- Case Background: The lawsuit alleges that the defendants made false and/or misleading statements regarding their New Drug Application (NDA) and failed to disclose the significance of human factors in the use of their sublingual film, resulting in investor losses when the truth emerged.
- Law Firm's Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, showcasing its expertise and successful track record in this field.
See More
